STYLE (NCT03449173) a phase II Trial of Sunitinib in patients with type B3 Thymoma or Thymic Carcinoma in second and further lines
C. Proto,S. Manglaviti,G. Lo Russo, M. Musca,G. Galli,M. Imbimbo, M. Perrino, N. Cordua, E. Rulli,Z. Ballatore, A. Dal Maso, A. Chella,A. Sbrana,A. Prelaj,R. Ferrara,M. Occhipinti,M. Brambilla,A. De Toma,L. Mazzeo,T. Beninato, D. Signorelli, G. Massa, F.G. Greco, G. Calareso, D. Miliziano,R.M. Di Mauro, G. Mella, A. Lucarelli, A. Paggio,F. Galli, V. Torri,F.G.M. de Braud, G. Pasello,I. Petrini,R. Berardi, M. Ganzinelli,M. Garassino, P. Zucali Journal of Thoracic Oncology（2023）
摘要
This trial confirms the activity of sunitinib in TC patients, supporting its use as second line treatment.
更多查看译文
关键词
B3 thymoma,second line,sunitinib,thymic carcinoma
AI 理解论文
溯源树
样例
